<DOC>
	<DOC>NCT01211457</DOC>
	<brief_summary>This is an open label, phase I/II study to evaluate the safety and efficacy of sapacitabine administered in alternating cycles with decitabine in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML).</brief_summary>
	<brief_title>Study of Sapacitabine in Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Newly diagnosed AML based on WHO classification Age 70 years or older for whom the treatment of choice is lowintensity therapy by investigator assessment or who has refused intensive induction therapy recommended by investigator ECOG performance status 02 Adequate renal function Adequate liver function Able to swallow capsules Ability to understand and willingness to sign the informed consent form AML is of the subtype of acute promyelocytic leukemia or extramedullary myeloid tumor without bone marrow involvement Having received any systemic anticancer therapy for AML or received treatment with hypomethylating agents or cytotoxic chemotherapy for the preceding MDS or MPD Known central nervous system (CNS) involvement by leukemia Uncontrolled intercurrent illness including Known hypersensitivity to decitabine Known to be HIVpositive</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>